About the conference
The AgencyIQ Team is excited to attend RAPS Convergence 2023, this October 3-5, at Palais des Congrès de Montréal in Montréal, QC.
The conference will be covering the latest developments in medical devices, biopharmaceuticals, and IVDs, and allows regulatory affairs professionals and industry partners to connect and collaborate.
Exclusive Content
“FDA Forecast: The Biggest Issues Facing the FDA in 2024”
Alexander Gaffney, Executive Director of Regulatory Policy and Intelligence, and Laura DiAngelo, Research Director, presented “FDA Forecast: The Biggest Issues Facing the FDA in 2024” at RAPS Convergence.
Whether you missed the presentation, or just want your own copy, sign up now to download the slides.
Meet us there
Visit us at booth #411 to connect with our team of regulatory experts, experience AgencyIQ’s subscriber dashboard, preview premium content, and receive exclusive gifts.
Alexander Gaffney, MS, RAC
Executive Director, Regulatory Policy and Intelligence
Laura DiAngelo, MPH
Research Director
Kirsten Messmer, PhD, RAC
Senior Research Analyst
Miea Hicks
Product Manager
Joshua Sztorc
Director, Regulatory Solutions
Rachel Gartlan
Senior Account Manager
Attend Our Presentations
The AgencyIQ Research Team will also be participating in the following sessions:
Wednesday, October 4
2:00pm – 3:00pm EDT
FDA Forecast 2024: What pharmaceutical and biotech regulatory professionals can expect from FDA next year
Session Leader:
Alexander Gaffney, MS, RAC
Executive Director, Regulatory Policy and Intelligence, POLITICO’s AgencyIQ
Presentation Description: With the start of the new fiscal year, regulatory professionals working in the pharmaceutical and biotech industries are wondering what the regulatory year ahead looks like for the FDA – and the life sciences industry. In this 60-minute, fast-paced and lively session, leading regulatory intelligence professionals will present evidence-based predictions on what FDA will do in the coming fiscal year, with a focus on pharmaceuticals, biologics and cell and gene therapy products.
Wednesday, October 4
3:30pm – 4:30pm EDT
FDA Forecast 2024: What device and diagnostics regulatory professionals can expect from FDA next year
Presenters:
Alexander Gaffney, MS, RAC
Executive Director, Regulatory Policy and Intelligence, POLITICO’s AgencyIQ
Laura DiAngelo, MPH
Director, Research, POLITICO’s AgencyIQ
Presentation Description: With the start of the new fiscal year just days before the RAPS Convergence, regulatory professionals working in the medical device and diagnostics industries are wondering what the regulatory year ahead looks like for the FDA – and industry. In this 60-minute, fast-paced and lively session, leading regulatory intelligence professionals will present our evidence-based predictions on what we think FDA will be focused on most in the coming fiscal year, with a focus on medical devices, digital health products, and diagnostics.
Wednesday, October 4
3:30pm – 4:30pm EDT
Navigating global regulatory frameworks for cell and gene therapy development
Presenter:
Kirsten Messmer, PhD, RAC
Senior Research Analyst, POLITICO’s AgencyIQ
Presentation Description: The potential of advanced therapies to treat and/or cure many rare diseases and life-threatening conditions has drawn the industry’s interest for product development. The number of innovative technologies under development has increased almost exponentially over the past few years. Additionally, medicinal product developers increasingly aim to develop investigational products for the global market in part because some of these therapies may only treat a few patients globally. However, global development also means navigating a heterogeneous array of global frameworks for advanced therapies.
Thursday, October 5
11:15 AM – 11:40 AM EDT
Discover! Stage (#123)
FDA Forecast: The Biggest Issues Facing the FDA in 2024
Speakers:
Alexander Gaffney, MS, RAC
Executive Director, Regulatory Policy and Intelligence, POLITICO’s AgencyIQ
Laura DiAngelo, MPH
Director, Research, POLITICO’s AgencyIQ
Presentation Description: What do regulatory professionals need to be tracking as the FDA begins its new fiscal year?
Join regulatory policy and intelligence experts for a fast-paced, lively, and informative look at the biggest regulatory issues that the FDA will be facing in 2024. This session will identify key regulatory issues, critical legislative changes, upcoming guidance and pilot programs from key user fee programs, and our predictions about where FDA is headed next.
Stay Connected
Sign up for our free daily newsletter, FDA Today, to gain actionable and insightful explanations of the latest FDA developments that impact the life sciences industry and access a preview of the invaluable, premium research typically only available to AgencyIQ subscribers.
About AgencyIQ
The modern regulatory environment is complex and ever changing. AgencyIQ, a division of POLITICO, is a strategic partner and extension of clients’ teams by offering regulatory professionals reliable access to analysis and insights, real-time data, and non-partisan journalism. Our vision is to enable businesses to deeply understand, seamlessly track and productively engage regulators to accelerate action and improve outcomes.